Suppr超能文献

丙型肝炎病毒1b型NS5A区域在干扰素或干扰素-利巴韦林联合治疗期间的准种进化

Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.

作者信息

Veillon Pascal, Payan Christopher, Le Guillou-Guillemette Hélène, Gaudy Catherine, Lunel Françoise

机构信息

Laboratory of Virology, Angers University Hospital, 4 rue Larrey, 49933 Angers cedex 9, France.

出版信息

World J Gastroenterol. 2007 Feb 28;13(8):1195-203. doi: 10.3748/wjg.v13.i8.1195.

Abstract

AIM

To evaluate the implication of substitutions in the hepatitis C virus (HCV) non-structural 5A (NS5A) protein in the resistance of HCV during mono-interferon (IFN) or combined IFN-ribavirin (IFN-R) therapy. Although NS5A has been reported to interact with the HCV RNA-dependent RNA polymerase, NS5B, as well as with many cellular proteins, the function of NS5A in the life cycle of HCV remains unclear.

METHODS

HCV quasispecies were studied by cloning and sequencing of sequential isolates from patients infected by HCV genotype 1b. Patients were treated by IFN-alpha2b for 3 mo followed by IFN-alpha2b alone or combined IFN-R therapy for 9 additional months. Patients were categorized into two groups based on their response to the treatments: 7 with sustained virological response (SVR) (quasispecies = 150) and 3 non-responders (NR) to IFN-R (quasispecies = 106).

RESULTS

Prior to treatment, SVR patients displayed a lower complexity of quasispecies than NR patients. Most patients had a decrease in the complexity of quasispecies during therapy. Analysis of amino acids substitutions showed that the degree of the complexity of the interferon sensitivity-determining region (ISDR) and the V3 domain of NS5A protein was able to discriminate the two groups of patients. Moreover, SVR patients displayed more variability in the NS5A region than NR patients.

CONCLUSION

These results suggest that detailed molecular analysis of the NS5A region may be important for understanding its function in IFN response during HCV 1b infection.

摘要

目的

评估丙型肝炎病毒(HCV)非结构5A(NS5A)蛋白中的替换在单干扰素(IFN)或联合干扰素-利巴韦林(IFN-R)治疗期间对HCV耐药性的影响。尽管已有报道称NS5A与HCV RNA依赖性RNA聚合酶NS5B以及许多细胞蛋白相互作用,但NS5A在HCV生命周期中的功能仍不清楚。

方法

通过对感染HCV 1b基因型患者的连续分离株进行克隆和测序来研究HCV准种。患者先接受α-干扰素2b治疗3个月,随后单独使用α-干扰素2b或联合IFN-R治疗9个月。根据患者对治疗的反应将其分为两组:7例获得持续病毒学应答(SVR)(准种=150)和3例对IFN-R无应答(NR)(准种=106)。

结果

治疗前,SVR患者的准种复杂性低于NR患者。大多数患者在治疗期间准种复杂性降低。氨基酸替换分析表明,NS5A蛋白的干扰素敏感性决定区(ISDR)和V3结构域的复杂性程度能够区分两组患者。此外,SVR患者的NS5A区域比NR患者表现出更多变异性。

结论

这些结果表明,对NS5A区域进行详细的分子分析对于理解其在HCV 1b感染期间IFN应答中的功能可能很重要。

相似文献

3
Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
Infect Genet Evol. 2009 Jul;9(4):689-98. doi: 10.1016/j.meegid.2008.11.001. Epub 2008 Nov 21.

引用本文的文献

4
5
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.
PLoS Pathog. 2009 Nov;5(11):e1000658. doi: 10.1371/journal.ppat.1000658. Epub 2009 Nov 13.
7
The quasispecies nature and biological implications of the hepatitis C virus.
Infect Genet Evol. 2009 Dec;9(6):1158-67. doi: 10.1016/j.meegid.2009.07.011. Epub 2009 Aug 8.
8
Natural products as promising drug candidates for the treatment of hepatitis B and C.
Acta Pharmacol Sin. 2009 Jan;30(1):25-30. doi: 10.1038/aps.2008.5. Epub 2008 Dec 8.
9
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.
PLoS One. 2008 May 7;3(5):e2123. doi: 10.1371/journal.pone.0002123.

本文引用的文献

6
Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
J Clin Microbiol. 2005 Feb;43(2):750-4. doi: 10.1128/JCM.43.2.750-754.2005.
7
Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
J Clin Virol. 2005 Feb;32(2):86-91. doi: 10.1016/j.jcv.2004.08.004.
9
Changes of HCV quasispecies during combination therapy with interferon and ribavirin.
Hepatol Res. 2004 Jun;29(2):89-96. doi: 10.1016/j.hepres.2004.02.014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验